Ionis Pharmaceuticals, Inc. $IONS Shares Bought by Exome Asset Management LLC

Exome Asset Management LLC increased its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 121.0% during the first quarter, Holdings Channel.com reports. The fund owned 135,616 shares of the company’s stock after buying an additional 74,249 shares during the period. Ionis Pharmaceuticals makes up about 3.5% of Exome Asset Management LLC’s portfolio, making the stock its 6th biggest position. Exome Asset Management LLC’s holdings in Ionis Pharmaceuticals were worth $4,092,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the stock. Signaturefd LLC increased its position in Ionis Pharmaceuticals by 45.6% during the 1st quarter. Signaturefd LLC now owns 1,382 shares of the company’s stock valued at $42,000 after purchasing an additional 433 shares during the period. Ancora Advisors LLC bought a new stake in shares of Ionis Pharmaceuticals in the 1st quarter valued at $60,000. Raiffeisen Bank International AG acquired a new stake in shares of Ionis Pharmaceuticals during the fourth quarter worth $62,000. CWM LLC increased its position in shares of Ionis Pharmaceuticals by 18.7% during the first quarter. CWM LLC now owns 2,435 shares of the company’s stock worth $73,000 after buying an additional 384 shares during the period. Finally, Exchange Traded Concepts LLC lifted its holdings in Ionis Pharmaceuticals by 1,722.5% in the first quarter. Exchange Traded Concepts LLC now owns 3,244 shares of the company’s stock valued at $98,000 after buying an additional 3,066 shares during the period. 93.86% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, Director Joseph H. Wender sold 11,200 shares of Ionis Pharmaceuticals stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $60.14, for a total transaction of $673,568.00. Following the transaction, the director directly owned 108,835 shares of the company’s stock, valued at $6,545,336.90. The trade was a 9.33% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Shannon L. Devers sold 3,162 shares of the stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $61.02, for a total transaction of $192,945.24. Following the completion of the sale, the executive vice president owned 15,009 shares of the company’s stock, valued at approximately $915,849.18. This represents a 17.40% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 464,141 shares of company stock valued at $26,772,779 in the last three months. Insiders own 2.60% of the company’s stock.

Ionis Pharmaceuticals Price Performance

Shares of NASDAQ IONS opened at $61.00 on Tuesday. The stock has a market cap of $9.72 billion, a price-to-earnings ratio of -33.15 and a beta of 0.28. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.86 and a current ratio of 2.87. Ionis Pharmaceuticals, Inc. has a fifty-two week low of $23.95 and a fifty-two week high of $62.08. The firm’s 50-day simple moving average is $44.08 and its 200 day simple moving average is $36.60.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.51. The firm had revenue of $452.00 million during the quarter, compared to analyst estimates of $270.90 million. Ionis Pharmaceuticals had a negative return on equity of 45.29% and a negative net margin of 28.25%.The company’s revenue for the quarter was up 100.9% on a year-over-year basis. During the same period in the previous year, the company posted ($0.45) EPS. Ionis Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Royal Bank Of Canada upped their target price on Ionis Pharmaceuticals from $70.00 to $80.00 and gave the company an “outperform” rating in a research report on Thursday, September 4th. Barclays lifted their price objective on shares of Ionis Pharmaceuticals from $58.00 to $78.00 and gave the company an “overweight” rating in a research note on Wednesday, September 3rd. Needham & Company LLC increased their target price on shares of Ionis Pharmaceuticals from $55.00 to $70.00 and gave the stock a “buy” rating in a research note on Tuesday, September 2nd. Raymond James Financial raised their price target on shares of Ionis Pharmaceuticals from $60.00 to $64.00 and gave the stock a “strong-buy” rating in a report on Thursday, July 31st. Finally, Jefferies Financial Group upped their price objective on shares of Ionis Pharmaceuticals from $83.00 to $96.00 and gave the company a “buy” rating in a report on Tuesday, September 2nd. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $67.88.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.